HGEN - Humanigen secures $80M loan facility from Hercules Capital
Humanigen (HGEN) has obtained a term loan facility from Hercules Capital (HTGC) for up to $80M of secured debt financing.“The term loan facility provides working capital to support the production of lenzilumab, strengthens our balance sheet and increases our financial flexibility as we prepare for the potential Emergency Use Authorization and commercial launch of lenzilumab in 2021,” Humanigen CEO Cameron Durrant said.The facility consists of a $25M initial term loan, with up to an additional $55M available for future draws, and also provides for an interest-only period and the four-year term is extendable under certain conditions.
For further details see:
Humanigen secures $80M loan facility from Hercules Capital